ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Structure Therapeutics (GPCR) pipeline and stated timing

Name in SEC filings: Structure Therapeutics Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
Aleniglipron/data readoutStage not stated 20268-K ·
AleniglipronTopline/data readoutStage not statedQ4 20268-K ·
AleniglipronTopline/data readoutStage not statedQ4 20268-K ·
ACCG-2671Topline/data readoutOther 20278-K ·

Source: ORION, orionbiotechai.com/company/GPCR, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/GPCR

Nearest upcoming stated timing: Aleniglipron · Topline/data readout · Q4 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
ACCG-2671Clinical results1H 2027
“participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

AleniglipronClinical resultsQ4 2026
“SWITCH Data”

Filed · EX-99.2

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsQ4 2026
“Body Comp Data”

Filed · EX-99.2

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsQ4 2026
“T2DM/Obesity Data”

Filed · EX-99.2

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe fourth quarter of 2026
“We anticipate data from the SWITCH trial in the fourth quarter of 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe second half of 2026
“Structure plans to report new data from the following aleniglipron clinical trials in the second half of 2026”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“Data are expected in Q4 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe fourth quarter of 2026
“We anticipate topline results from the body composition trial in the fourth quarter of 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe second half of 2026
“Structure plans to report new data from the following aleniglipron clinical trials in the second half of 2026”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“Data are expected in Q4 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe fourth quarter of 2026
“We anticipate data from the T2DM trial in the fourth quarter of 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe second half of 2026
“Structure plans to report new data from the following aleniglipron clinical trials in the second half of 2026”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“Data are expected in Q4 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe fourth quarter of 2026
“We anticipate data from the SWITCH study in the fourth quarter of 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“Data are expected in Q4 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe fourth quarter of 2026
“We anticipate topline results from the body composition study in the fourth quarter of 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“Data from the Body Composition and Type 2 Diabetes / Obesity data expected in Q4 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsQ4 2026
“The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsQ4 2026
“Data are expected in Q4 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsthe fourth quarter of 2026
“We anticipate data from the T2DM study in the fourth quarter of 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

AleniglipronClinical resultsQ4 2026
“Data from the Body Composition and Type 2 Diabetes / Obesity data expected in Q4 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

AleniglipronClinical resultsQ4 2026
“Data are expected in Q4 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained program pages

Watch GPCR

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for GPCR. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See GPCR in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.1H means January–June and 2H means July–December of the stated year, unless the company uses a different fiscal year.